The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 23, 2018

Filed:

Jan. 10, 2017
Applicant:

Techfields Pharma Co., Ltd., Suzhou, Jiangsu, CN;

Inventors:

Chongxi Yu, Kensington, MD (US);

Lina Xu, Shanghai, CN;

Assignee:

Techfields Pharma Co., Ltd., Suzhou, Jiangsu, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/625 (2006.01); A61K 31/60 (2006.01); A61K 31/216 (2006.01); A61K 9/14 (2006.01); A61K 31/24 (2006.01); A61L 15/44 (2006.01); A61K 47/48 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01);
U.S. Cl.
CPC ...
A61K 31/216 (2013.01); A61K 9/0014 (2013.01); A61K 9/0043 (2013.01); A61K 9/0073 (2013.01); A61K 9/703 (2013.01); A61K 31/24 (2013.01); A61K 47/48023 (2013.01); A61L 15/44 (2013.01); A61L 2300/21 (2013.01);
Abstract

The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.


Find Patent Forward Citations

Loading…